Business Wire

Philip Morris International Recognized as Top Employer in Africa Third Year in a Row

Share

Philip Morris International Inc. (PMI) (NYSE: PM) today was recognized for the third consecutive year as a Top Employer in Africa, awarding the company’s commitment to creating an excellent work environment for its employees.

This certification is the result of independent assessment by the Top Employers Institute, which has also presented national-level awards to PMI affiliate teams in South Africa, Senegal, Morocco, Algeria, Egypt, Nigeria, and Tunisia for the first time. Since 2014, PMI has received Top Employer certifications in 45 countries. PMI was recognized as a Global Top Employer in 2018 for the second time, and Africa is the first of our regions to be recognized as a Top Employer in the 2019 certification cycle. We have previously been certified in 5 regions: Africa, the European Union, the Middle East, Latin America, and North America.

“We are focused on building a vibrant, engaging, and inclusive environment that makes our employees feel welcome and that they are essential to the success of the company,” said Alejandro Lamas, PMI Vice President People and Culture, Eastern Europe, Middle East and Africa and Duty Free. “It is an honor to be recognized for the third year in a row as a Top Employer in Africa. This award recognizes our efforts to provide the right challenges, support, and development to our employees so they can focus on driving our company’s transformation towards a smoke-free future.”

PMI employs approximately 81,000 people worldwide, and offers compelling reward programs in the areas of compensation and benefits, health and well-being, financial planning, and education.

Top Employer certification

The Top Employer certification is awarded by the Top Employer Institute following a robust assessment validated by the auditing firm Grant Thornton. Assessment areas include compensation and employee benefits, career development, working conditions and training and development.

###

Philip Morris International: Who We Are

We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products that are a much better consumer choice than continuing to smoke cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirements. Our vision is that these products ultimately replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. For more information, see our PMI and PMIScience websites.

Contact information

Philip Morris International
Media enquiries
Ryan Sparrow
+41 (0)58 242 4500
ryan.sparrow@pmi.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CESTPress release

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a

European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr

Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CESTPress release

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit

JRJ Group Announces Sale of ETX Capital to Guru Capital28.5.2020 15:30:00 CESTPress release

JRJ Group, a leading international private equity investment firm focused on the financial services sector and growth situations, is pleased to announce that it has agreed to terms for the sale of ETX Capital, one of the fastest growing international providers of multi-asset CFDs and spread betting products, to a fund associated with Guru Capital, a Switzerland-based private equity firm with specific experience in the CFD space. Terms of the transaction were not disclosed. Roger Nagioff, Founding Partner of JRJ Group, said, “During JRJ’s ownership, we have invested in bolt-on acquisitions and enhanced the technology of the firm. We are delighted with the strength and resilience of the platform we have built, alongside the management team and employees, and we wish the enterprise every success in its next stage of growth.” “We are grateful of JRJ Group’s support, and we look forward to growing the business with the Guru Capital team, who have substantial experience in the CFD sector,” s

eLichens Launches eStore for US and EU Markets28.5.2020 15:00:00 CESTPress release

French start-up eLichens has launched its online store last week. eLos, for eLichens Outdoor Station, can now be purchased online by US and EU customers. Japan and other areas will soon join the list. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005117/en/ (Photo: Business Wire) eLos is a wireless, solar-powered air quality station. eLos provides citizens, communities and organizations the most accurate and complete real-time data about air quality, wherever they need it. Visit the store and learn more about eLos : https://www.elichens.com/store/elos View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005117/en/Contact information Marc Attia, press@elichens.com

SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate28.5.2020 14:24:00 CESTPress release

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced in vitro data demonstrating that SAB-185, its COVID-19 therapeutic candidate, has highly-potent neutralizing antibodies to SARS-CoV-2 that are four times higher than the most potent human convalescent plasma serum sample evaluated. The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on track to begin human trials in early summer. “These data indicate this human polyclonal antibody therapeutic has potent neutralizing activity against live SARS-CoV-2. The neutralizing titers of SAB-185 are significantly higher than those of the most potent plasma of recovered COVID-19 patients we’ve been able to source,” said William B. Klimstra, PhD Associate Professor of Microbio